Paul Koker

403 total citations
13 papers, 300 citations indexed

About

Paul Koker is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Genetics. According to data from OpenAlex, Paul Koker has authored 13 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 7 papers in Physiology and 1 paper in Genetics. Recurrent topics in Paul Koker's work include Cystic Fibrosis Research Advances (9 papers), Asthma and respiratory diseases (6 papers) and Inhalation and Respiratory Drug Delivery (4 papers). Paul Koker is often cited by papers focused on Cystic Fibrosis Research Advances (9 papers), Asthma and respiratory diseases (6 papers) and Inhalation and Respiratory Drug Delivery (4 papers). Paul Koker collaborates with scholars based in United States, Germany and Canada. Paul Koker's co-authors include Michael W. Konstan, Siladitya Bhattacharya, Gerd Döring, Kathleen A. Hilliard, Larry C. Lands, A. Hamilton, Alexander Staab, Sonya L. Heltshe, David W. Hudgel and David A. Lewis and has published in prestigious journals such as PLoS ONE, CHEST Journal and Journal of Allergy and Clinical Immunology.

In The Last Decade

Paul Koker

13 papers receiving 299 citations

Peers

Paul Koker

PRM

PHYSI

EPIDE

EMS

Iulia Ioan France

Geneline Sajol United States

Leslie Baitinger United States

Sung‐Il Woo South Korea

Sandra Söhler Germany

Nina L. Church United States

Myongsoon Sung South Korea

Andrew Gelfand United States

M. Grosclaude France

Elizabeth A. Nguyen United States

Iulia Ioan France

Paul Koker

149 ×0.6

PRM

166 ×1.2

PHYSI

11 ×0.5

EPIDE

21 ×0.9

EMS

16 ×0.8

Citations per year, relative to Paul Koker Paul Koker (= 1×) peers Iulia Ioan

Countries citing papers authored by Paul Koker

Since Specialization

Citations

This map shows the geographic impact of Paul Koker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Koker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Koker more than expected).

Fields of papers citing papers by Paul Koker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Koker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Koker. The network helps show where Paul Koker may publish in the future.

Co-authorship network of co-authors of Paul Koker

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Koker. A scholar is included among the top collaborators of Paul Koker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Koker. Paul Koker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Ratjen, Félix, Paul Koker, David E. Geller, et al.. (2015). Tiotropium Respimat® in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis. 14(5). 608–614. 9 indexed citations

Maleki-Yazdi, M. Reza, Ekkehard Beck, Alan Hamilton, et al.. (2015). A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease. Respiratory Medicine. 109(5). 596–605. 14 indexed citations

Kamin, Wolfgang, David Krackhardt, Sabine Kattenbeck, et al.. (2015). A Handling Study to Assess the Use of the Respimat® Soft Mist™ Inhaler in Children Aged 4–12 Years. Pulmonary Therapy. 1(1). 53–63. 2 indexed citations

Konstan, Michael W., Ashish Sharma, Petra Moroni-Zentgraf, Fei Wang, & Paul Koker. (2014). Safety, Tolerability, and Plasma Exposure of Tiotropium Respimat ^® in Children and Adults with Cystic Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 28(2). 137–144. 6 indexed citations

Bradley, Judy, Paul Koker, Qiqi Deng, et al.. (2014). Testing Two Different Doses of Tiotropium Respimat® in Cystic Fibrosis: Phase 2 Randomized Trial Results. PLoS ONE. 9(9). e106195–e106195. 25 indexed citations

Konstan, Michael W., Gerd Döring, Sonya L. Heltshe, et al.. (2014). A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. Journal of Cystic Fibrosis. 13(2). 148–155. 105 indexed citations

Sharma, Ashish, David E. Geller, Petra Moroni-Zentgraf, et al.. (2014). Pooled analysis of tiotropium Respimat® pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology & Therapeutics. 29(2). 217–223. 4 indexed citations

Geller, David E., Paul Koker, J.S. Elborn, et al.. (2013). 64 Tiotropium in cystic fibrosis: Pooled analysis of phase II and III randomized, controlled trials. Journal of Cystic Fibrosis. 12. S64–S64. 3 indexed citations

Ratjen, Félix, Paul Koker, David E. Geller, et al.. (2013). 61 Tiotropium Respimat in cystic fibrosis: Efficacy and safety results of phase III randomized placebo-controlled trial. Journal of Cystic Fibrosis. 12. S64–S64. 3 indexed citations

10.

Elborn, J.S., et al.. (2011). 80* A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 μg and 5 μg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis. 10. S21–S21. 4 indexed citations

11.

Korducki, Lawrence, et al.. (2009). Four Weeks Once Daily Treatment with BI 1744 CL, a Novel Long-Acting ß ₂ -Agonist, Is Effective in COPD Patients.. A6183–A6183. 17 indexed citations

12.

Martin, Richard J., Philip L. Smith, David W. Hudgel, et al.. (1999). Effect of Ipratropium Bromide Treatment on Oxygen Saturation and Sleep Quality in COPD. CHEST Journal. 115(5). 1338–1345. 74 indexed citations

13.

Diamond, Louis S., Robert J. Dockhorn, Jay Grossman, et al.. (1995). A dose-response study of the efficacy and safety of ipratropium bromide nasal spray in the treatment of the common cold. Journal of Allergy and Clinical Immunology. 95(5). 1139–1146. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact